"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Abstract Text:

Roy West,E Keith Borden,Jean-Paul Collet,Nigel S B Rawson,Robert S Tonks,

BACKGROUND: Facing financial pressures, the provinces and territories have chosen to use "cost-effectiveness" for making decisions about drug listings. This study examines the scientific basis for the procedures used to determine cost-effectiveness in 5 Canadian provinces. METHODS: Questionnaires were mailed to key provincial informants asking about the respondent's expertise and role, the administrative and scientific basis for decision-making, organizational structures and other factors in the scientific evaluation and decision-making process, and the transparency of the process. There were also questions about the data required and received and their importance, the place of cost-effectiveness and other economic impact evaluations, the data sources for them, and the use of follow-up monitoring to evaluate the decisions made. RESULTS: Information required by the provinces for decision-making about cost-effectiveness is not available to them at the time of their decisions about listing new medications. The primary sources of data on both efficacy and cost-effectiveness are pharmaceutical companies. Efficacy information is generated in a scientifically rigorous manner, whereas the effectiveness and cost data are estimates potentially subject to biases and evaluated by judgement (expert opinion) alone. Moreover, there is no collaboration in the assessment process between provinces. The outcomes are large differences between provinces in the decisions made and, hence, in the pharmaceuticals accessible to residents. CONCLUSIONS: Current methods for making decisions about provincial drug listings are based on inadequate data, and the lack of consistency in the provinces' decisions suggest they may be scientifically flawed. We recommend establishing a single national scientific review committee, with re-evaluation of each drug's cost-effectiveness after a suitable period of monitored use.

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Publishing Authors By Initials

R West,EK Borden,JP Collet,NS Rawson,RS Tonks,

For similar investigative techniques: epidemiologic methods: data collection: questionnaires research abstracts see: investigative techniques: epidemiologic methods: data collection: questionnaires research

PUBMED ID PMID:

MEDLINE DATE: 2002 Nov-Dec

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Canadian journal of public health. Revue canadienn

VOLUME: 93

Page Numbers: 421-5

Journal Abbreviation:

ISSN: 0008-4263

DAY: 13

MONTH: 02

YEAR: 2008

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372714

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Keywords Mesh Terms:

KEYWORDS: Questionnaires

MESH TERMS: economics

Chemical & Substance for Abstract: "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.

AFFILIATION: Division of Community Health, Memorial University of Newfoundland, Health Sciences Centre, St. John's, NF A1B 3V6. roywest@mun.ca

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Public Health

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement Related Publications

• "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
• A 5.8-kDa component of manuka honey stimulates immune cells via TLR4.
• A COMPARISON OF DARK ADAPTATION IN MINERS WITH THEIR NUTRITIONAL STATE.
• A comparison of dark adaptation in miners with their nutritional state.
• A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells.
• A-BETA-LIPOPROTEINAEMIA WITH SPECIAL REFERENCE TO THE VISUAL DEFECT.
• BIOCHEMICAL FINDINGS IN HUMAN RETINITIS PIGMENTOSA WITH PARTICULAR RELATION TO VITAMIN A DEFICIENCY.
• Cabin fever.
• Combined action of diamox and potassium bicarbonate in the treatment of of chronic glaucoma.
• Effect of diamox on plasma bicarbonate and on the electrolyte balance in relation to intra-ocular pressure in man.
• Experimental exophthalmos in rats due to thiouracil and cortisone.
• Lithium intoxications induced by dieting and saunas.
• Lyme wars.
• Lysophospholipid acyltransferases: Novel potential regulators of the inflammatory response and target for new drug discovery.
• Poor communication, poor training, and chaotic drug rounds contribute to drug errors.
• RETINITIS PIGMENTOSA: VITAMIN A SERUM LEVELS IN RELATION TO CLINICAL FINDINGS.
• Safer by design.
• Some observations on the water drinking test in glaucomatous and non-glaucomatous subjects.